Alps Advisors Inc. purchased a new stake in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE – Get Rating) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 26,665 shares of the biotechnology company’s stock, valued at approximately $112,000.
A number of other large investors also recently made changes to their positions in the stock. State Street Corp lifted its stake in shares of Concert Pharmaceuticals by 7.2% in the 1st quarter. State Street Corp now owns 75,798 shares of the biotechnology company’s stock valued at $255,000 after purchasing an additional 5,058 shares during the period. Roanoke Asset Management Corp NY acquired a new position in shares of Concert Pharmaceuticals in the 1st quarter valued at $34,000. Acadian Asset Management LLC lifted its stake in shares of Concert Pharmaceuticals by 1.4% in the 1st quarter. Acadian Asset Management LLC now owns 794,106 shares of the biotechnology company’s stock valued at $2,675,000 after purchasing an additional 11,293 shares during the period. Virtu Financial LLC acquired a new position in shares of Concert Pharmaceuticals in the 1st quarter valued at $47,000. Finally, Jane Street Group LLC bought a new stake in shares of Concert Pharmaceuticals in the 1st quarter valued at $56,000. Institutional investors and hedge funds own 82.77% of the company’s stock.
Analyst Ratings Changes
A number of research firms recently commented on CNCE. Truist Financial upped their price objective on shares of Concert Pharmaceuticals from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, September 13th. StockNews.com cut shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Jonestrading began coverage on shares of Concert Pharmaceuticals in a research report on Wednesday, August 24th. They issued a “buy” rating and a $17.00 price objective for the company.
Concert Pharmaceuticals Trading Up 0.4 %
Concert Pharmaceuticals Profile
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition.
- Get a free copy of the StockNews.com research report on Concert Pharmaceuticals (CNCE)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.